A Systematic Approach to the Treatment of HIV and Hepatitis C Virus Infection in the Inner City: A Canadian Perspective
The treatment of injection drug users (IDUs) coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) presents multiple challenges, many of which could be addressed by the development of directly observed therapy programs. This is made all the more feasible by the validation of...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 2005-07, Vol.41 (Supplement-1), p.S73-S78 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S78 |
|---|---|
| container_issue | Supplement-1 |
| container_start_page | S73 |
| container_title | Clinical infectious diseases |
| container_volume | 41 |
| creator | Conway, Brian Grebely, Jason Tossonian, Harout Lefebvre, Dennis Vlaming de, Stanley |
| description | The treatment of injection drug users (IDUs) coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) presents multiple challenges, many of which could be addressed by the development of directly observed therapy programs. This is made all the more feasible by the validation of once-daily treatment regimens for HIV. We have demonstrated that virological suppression can be achieved and maintained in as many as 80% of active IDUs who have received highly active antiretroviral therapy for 48 months. This approach has now been validated in first- and second-line therapy, as well as for the treatment of bacterial infections in this population, achieving therapeutic results similar to those reported in the general population. The model is now being applied to the treatment of HCV infection, focusing on patients with infection due to HCV genotype 2 or 3, in whom the likelihood of response may exceed 80%. Our ultimate goal is to ensure that, even in treating IDUs in the inner city, no patient is left behind. |
| doi_str_mv | 10.1086/429500 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_17509788</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>4463324</jstor_id><sourcerecordid>4463324</sourcerecordid><originalsourceid>FETCH-LOGICAL-c426t-d2fcc1e0d16bb2f3a83898633791fc3e7826c061ffcd370a9e9ac659d580e7243</originalsourceid><addsrcrecordid>eNpdkUtv1DAUhSNERR_AL0DIYtFdih3HL3ajCMhUFSAoI8TG8jg3qoeJE2wHmH9ftzNqJVb3Sufz0T0-RfGS4AuCJX9bV4ph_KQ4IYyKkjNFnuYdM1nWksrj4jTGDcaESMyeFceEV5xxok6Kvwv0bRcTDCY5ixbTFEZjb1AaUboBdB3ApAF8QmOP2uUKGd-hFqYMJxdRg1YuzBEtfQ82udEj5-_fLb2HgBqXdu_QAjXGm84Zj75AiNMd-QeeF0e92UZ4cZhnxfcP76-btrz6_HHZLK5KW1c8lV3VW0sAd4Sv11VPTQ6jJKdUKNJbCkJW3GJO-t52VGCjQBmb03dMYhBVTc-K871vDvZ7hpj04KKF7dZ4GOeoiWBYCSkz-OY_cDPOwefbdEWUqjmj7NHNhjHGAL2eghtM2GmC9V0Pet9DBl8f3Ob1AN0jdvj4DLzaA5uYxvCg13XOdn92uZdd7ubfg2zCL80FFUy3P37qVfPp6-pStVrQWye1mPA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>219946535</pqid></control><display><type>article</type><title>A Systematic Approach to the Treatment of HIV and Hepatitis C Virus Infection in the Inner City: A Canadian Perspective</title><source>MEDLINE</source><source>Jstor Complete Legacy</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Conway, Brian ; Grebely, Jason ; Tossonian, Harout ; Lefebvre, Dennis ; Vlaming de, Stanley</creator><creatorcontrib>Conway, Brian ; Grebely, Jason ; Tossonian, Harout ; Lefebvre, Dennis ; Vlaming de, Stanley</creatorcontrib><description>The treatment of injection drug users (IDUs) coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) presents multiple challenges, many of which could be addressed by the development of directly observed therapy programs. This is made all the more feasible by the validation of once-daily treatment regimens for HIV. We have demonstrated that virological suppression can be achieved and maintained in as many as 80% of active IDUs who have received highly active antiretroviral therapy for 48 months. This approach has now been validated in first- and second-line therapy, as well as for the treatment of bacterial infections in this population, achieving therapeutic results similar to those reported in the general population. The model is now being applied to the treatment of HCV infection, focusing on patients with infection due to HCV genotype 2 or 3, in whom the likelihood of response may exceed 80%. Our ultimate goal is to ensure that, even in treating IDUs in the inner city, no patient is left behind.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1086/429500</identifier><identifier>PMID: 16265619</identifier><language>eng</language><publisher>United States: The University of Chicago Press</publisher><subject>AIDS ; Antiretroviral drugs ; Antiretroviral Therapy, Highly Active - methods ; Bacterial Infections - complications ; Bacterial Infections - drug therapy ; Canada ; Drug Interactions ; Drug therapy ; Genotype & phenotype ; Genotypes ; Hepatitis ; Hepatitis C virus ; Hepatitis C, Chronic - complications ; Hepatitis C, Chronic - drug therapy ; Highly active antiretroviral therapy ; HIV ; HIV infections ; HIV Infections - complications ; HIV Infections - drug therapy ; Human immunodeficiency virus ; Humans ; Infections ; Injections ; Methadone ; Poverty Areas ; Substance Abuse, Intravenous - complications ; Urban Population ; Virology ; Viruses</subject><ispartof>Clinical infectious diseases, 2005-07, Vol.41 (Supplement-1), p.S73-S78</ispartof><rights>Copyright 2005 The Infectious Diseases Society of America</rights><rights>Copyright University of Chicago, acting through its Press Jul 1, 2005</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c426t-d2fcc1e0d16bb2f3a83898633791fc3e7826c061ffcd370a9e9ac659d580e7243</citedby><cites>FETCH-LOGICAL-c426t-d2fcc1e0d16bb2f3a83898633791fc3e7826c061ffcd370a9e9ac659d580e7243</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/4463324$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/4463324$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,776,780,799,27903,27904,57996,58229</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16265619$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Conway, Brian</creatorcontrib><creatorcontrib>Grebely, Jason</creatorcontrib><creatorcontrib>Tossonian, Harout</creatorcontrib><creatorcontrib>Lefebvre, Dennis</creatorcontrib><creatorcontrib>Vlaming de, Stanley</creatorcontrib><title>A Systematic Approach to the Treatment of HIV and Hepatitis C Virus Infection in the Inner City: A Canadian Perspective</title><title>Clinical infectious diseases</title><addtitle>Clinical Infectious Diseases</addtitle><description>The treatment of injection drug users (IDUs) coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) presents multiple challenges, many of which could be addressed by the development of directly observed therapy programs. This is made all the more feasible by the validation of once-daily treatment regimens for HIV. We have demonstrated that virological suppression can be achieved and maintained in as many as 80% of active IDUs who have received highly active antiretroviral therapy for 48 months. This approach has now been validated in first- and second-line therapy, as well as for the treatment of bacterial infections in this population, achieving therapeutic results similar to those reported in the general population. The model is now being applied to the treatment of HCV infection, focusing on patients with infection due to HCV genotype 2 or 3, in whom the likelihood of response may exceed 80%. Our ultimate goal is to ensure that, even in treating IDUs in the inner city, no patient is left behind.</description><subject>AIDS</subject><subject>Antiretroviral drugs</subject><subject>Antiretroviral Therapy, Highly Active - methods</subject><subject>Bacterial Infections - complications</subject><subject>Bacterial Infections - drug therapy</subject><subject>Canada</subject><subject>Drug Interactions</subject><subject>Drug therapy</subject><subject>Genotype & phenotype</subject><subject>Genotypes</subject><subject>Hepatitis</subject><subject>Hepatitis C virus</subject><subject>Hepatitis C, Chronic - complications</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Highly active antiretroviral therapy</subject><subject>HIV</subject><subject>HIV infections</subject><subject>HIV Infections - complications</subject><subject>HIV Infections - drug therapy</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Infections</subject><subject>Injections</subject><subject>Methadone</subject><subject>Poverty Areas</subject><subject>Substance Abuse, Intravenous - complications</subject><subject>Urban Population</subject><subject>Virology</subject><subject>Viruses</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkUtv1DAUhSNERR_AL0DIYtFdih3HL3ajCMhUFSAoI8TG8jg3qoeJE2wHmH9ftzNqJVb3Sufz0T0-RfGS4AuCJX9bV4ph_KQ4IYyKkjNFnuYdM1nWksrj4jTGDcaESMyeFceEV5xxok6Kvwv0bRcTDCY5ixbTFEZjb1AaUboBdB3ApAF8QmOP2uUKGd-hFqYMJxdRg1YuzBEtfQ82udEj5-_fLb2HgBqXdu_QAjXGm84Zj75AiNMd-QeeF0e92UZ4cZhnxfcP76-btrz6_HHZLK5KW1c8lV3VW0sAd4Sv11VPTQ6jJKdUKNJbCkJW3GJO-t52VGCjQBmb03dMYhBVTc-K871vDvZ7hpj04KKF7dZ4GOeoiWBYCSkz-OY_cDPOwefbdEWUqjmj7NHNhjHGAL2eghtM2GmC9V0Pet9DBl8f3Ob1AN0jdvj4DLzaA5uYxvCg13XOdn92uZdd7ubfg2zCL80FFUy3P37qVfPp6-pStVrQWye1mPA</recordid><startdate>20050701</startdate><enddate>20050701</enddate><creator>Conway, Brian</creator><creator>Grebely, Jason</creator><creator>Tossonian, Harout</creator><creator>Lefebvre, Dennis</creator><creator>Vlaming de, Stanley</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><general>Oxford University Press</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T2</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope></search><sort><creationdate>20050701</creationdate><title>A Systematic Approach to the Treatment of HIV and Hepatitis C Virus Infection in the Inner City: A Canadian Perspective</title><author>Conway, Brian ; Grebely, Jason ; Tossonian, Harout ; Lefebvre, Dennis ; Vlaming de, Stanley</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c426t-d2fcc1e0d16bb2f3a83898633791fc3e7826c061ffcd370a9e9ac659d580e7243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>AIDS</topic><topic>Antiretroviral drugs</topic><topic>Antiretroviral Therapy, Highly Active - methods</topic><topic>Bacterial Infections - complications</topic><topic>Bacterial Infections - drug therapy</topic><topic>Canada</topic><topic>Drug Interactions</topic><topic>Drug therapy</topic><topic>Genotype & phenotype</topic><topic>Genotypes</topic><topic>Hepatitis</topic><topic>Hepatitis C virus</topic><topic>Hepatitis C, Chronic - complications</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Highly active antiretroviral therapy</topic><topic>HIV</topic><topic>HIV infections</topic><topic>HIV Infections - complications</topic><topic>HIV Infections - drug therapy</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Infections</topic><topic>Injections</topic><topic>Methadone</topic><topic>Poverty Areas</topic><topic>Substance Abuse, Intravenous - complications</topic><topic>Urban Population</topic><topic>Virology</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Conway, Brian</creatorcontrib><creatorcontrib>Grebely, Jason</creatorcontrib><creatorcontrib>Tossonian, Harout</creatorcontrib><creatorcontrib>Lefebvre, Dennis</creatorcontrib><creatorcontrib>Vlaming de, Stanley</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Conway, Brian</au><au>Grebely, Jason</au><au>Tossonian, Harout</au><au>Lefebvre, Dennis</au><au>Vlaming de, Stanley</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Systematic Approach to the Treatment of HIV and Hepatitis C Virus Infection in the Inner City: A Canadian Perspective</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clinical Infectious Diseases</addtitle><date>2005-07-01</date><risdate>2005</risdate><volume>41</volume><issue>Supplement-1</issue><spage>S73</spage><epage>S78</epage><pages>S73-S78</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><abstract>The treatment of injection drug users (IDUs) coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) presents multiple challenges, many of which could be addressed by the development of directly observed therapy programs. This is made all the more feasible by the validation of once-daily treatment regimens for HIV. We have demonstrated that virological suppression can be achieved and maintained in as many as 80% of active IDUs who have received highly active antiretroviral therapy for 48 months. This approach has now been validated in first- and second-line therapy, as well as for the treatment of bacterial infections in this population, achieving therapeutic results similar to those reported in the general population. The model is now being applied to the treatment of HCV infection, focusing on patients with infection due to HCV genotype 2 or 3, in whom the likelihood of response may exceed 80%. Our ultimate goal is to ensure that, even in treating IDUs in the inner city, no patient is left behind.</abstract><cop>United States</cop><pub>The University of Chicago Press</pub><pmid>16265619</pmid><doi>10.1086/429500</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 2005-07, Vol.41 (Supplement-1), p.S73-S78 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_17509788 |
| source | MEDLINE; Jstor Complete Legacy; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals |
| subjects | AIDS Antiretroviral drugs Antiretroviral Therapy, Highly Active - methods Bacterial Infections - complications Bacterial Infections - drug therapy Canada Drug Interactions Drug therapy Genotype & phenotype Genotypes Hepatitis Hepatitis C virus Hepatitis C, Chronic - complications Hepatitis C, Chronic - drug therapy Highly active antiretroviral therapy HIV HIV infections HIV Infections - complications HIV Infections - drug therapy Human immunodeficiency virus Humans Infections Injections Methadone Poverty Areas Substance Abuse, Intravenous - complications Urban Population Virology Viruses |
| title | A Systematic Approach to the Treatment of HIV and Hepatitis C Virus Infection in the Inner City: A Canadian Perspective |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T23%3A51%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Systematic%20Approach%20to%20the%20Treatment%20of%20HIV%20and%20Hepatitis%20C%20Virus%20Infection%20in%20the%20Inner%20City:%20A%20Canadian%20Perspective&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Conway,%20Brian&rft.date=2005-07-01&rft.volume=41&rft.issue=Supplement-1&rft.spage=S73&rft.epage=S78&rft.pages=S73-S78&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1086/429500&rft_dat=%3Cjstor_proqu%3E4463324%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=219946535&rft_id=info:pmid/16265619&rft_jstor_id=4463324&rfr_iscdi=true |